BioSpace News Archive

Insulet Corporation announced that the Company’s Omnipod DASH™ System has been named the 2020 Product of the Year in the Health Systems category.

Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that both domestic and international demand has surged for its novel coronavirus detection kits in recent weeks leading to increased product shipments, following the Food and Drug Administration’s (FDA) change in policy on February 29

NanoString Technologies, Inc. announced the pricing of $200 million aggregate principal amount of 2.625% convertible senior notes due 2025 in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.

Aridis Pharmaceuticals, Inc. announced that Vu Truong, Ph.D., Chief Executive Officer, will present at the 32nd Annual ROTH Conference on Monday, March 16, 2020 at 4:00 pm PDT.

Cure Alzheimer’s Fund, a nonprofit organization dedicated to funding the most promising research to prevent, slow or reverse Alzheimer’s disease, announced it has received a $1 million donation from Kristin Berg, Steven Berg and Laurie Berg Sapp in honor of their parents.

ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA”), today announced that it will report financial results for the fourth quarter and full year ending December 31, 2019 on Thursday, March 12, 2020 after the U.S. financial markets close

Idera Pharmaceuticals, Inc. (“Idera” or “the company”) (NASDAQ: IDRA) today announced completion of patient enrollment into ILLUMINATE-301, its registrational trial of tilsotolimod in combination with ipilimumab in patients with anti-PD-1 refractory advanced melanoma

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its fourth quarter and full-year 2019 financial results on Thursday, March 12, 2020 before market opens. Management will conduct a conference call and live webcast at 8:00 a.m. EST (7:00 a.m. CST) that day to discuss the financial results and to provide a business update.

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced the appointment of Mark Jacobson as Chief Operating Officer

Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today provided a business update and reported financial results for the fourth quarter and full year of 2019.